started · updated
US House panel discusses psychedelic-assisted therapy for veterans
A US House Committee on Veterans Affairs subcommittee held a hearing to discuss the potential implementation of psychedelic-assisted mental health treatments for veterans. Lawmakers questioned officials regarding the Department of Veterans Affairs ability to manage these labor-intensive therapies if the Food and Drug Administration grants approval.
Data from the Veterans Health Administration indicates that over 2 million veterans suffer from treatment-resistant depression, with approximately 180,000 potentially qualifying for treatments involving compounds such as MDMA, psilocybin, LSD, DMT, and ibogaine. The discussion comes amid concerns over veteran suicide rates, which reached nearly 6,500 in 2024.
In New Jersey, community leaders are also engaging with residents to gather input on the rollout of such therapies. The Camden Coalition has held town halls to address resident concerns regarding equitable access through Medicaid and Medicare, the importance of cultural sensitivity, and the need for clear evidence on efficacy and safety.
Entities
Camden Coalition · Department of Veterans Affairs · Food and Drug Administration · Mariannette Miller-Meeks · US House Committee on Veterans Affairs